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Abstract
Background: To assess the significance of alpha-fetoprotein (AFP) normalization as a prognostic surrogate after
stereotactic body radiotherapy (SBRT) for patients with small hepatocellular carcinoma (HCC).
Methods: Patients who underwent SBRT for primary or recurrent HCC were registered and a database thereof was
retrospectively reviewed. Among 165 total registered patients, 77 patients were selected who satisfied the following
criteria: (1) their AFP levels were > 20 ng/mL before SBRT, and (2) their AFP levels were checked within three
months after SBRT. Propensity score based matching analysis was performed to minimize potential confounding
bias. AFP normalization was defined as a reduction of AFP level to ≤ 20 ng/mL. Overall survival (OS) and
progression-free survival (PFS) curves were estimated by the Kaplan-Meier method.
Results: Thirty-seven (48.1 %) patients displayed AFP normalization (normalized group), while 40 (51.9 %) patients
comprised the non-normalized group. The OS rates at 3-year were 62.0 % and 44.0 % (p = 0.023), and the PFS rates
at 3-year were 27.9 % and 12.0 % (p = 0.019), in the normalized and non-normalized groups, respectively. Local
control rates were 97.2 % in the normalized group and 94.7 % in the non-normalized group at three years (p = 0.579).
In the propensity score matching cohort (25 pairs), OS and PFS were significantly longer in the normalized group than
in the non-normalized group (p = 0.017 and 0.049, respectively). The local control rates were 100 % in both matched
groups.
Conclusions: AFP normalization within three months after SBRT is a prognostic surrogate for OS and PFS in patients
with small HCC. AFP monitoring should be considered a useful tool for HCC patients with an elevated AFP
level before SBRT.
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Background
Surgical resection and liver transplantation are curative
treatment modalities for HCC. Surgical resection has
shown overall survival (OS) and recurrence-free survival
rates of 75–85 % and 83–92 %, respectively, at 3–4 years
[1, 2]. Liver transplantation has shown a five-year OS
rate of 70 %, as well as a low recurrence rate [1, 3].
However, only a small proportion of patients can be
treated using these modalities for various clinical rea-
sons. Another curative treatment of HCC is radiofre-
quency ablation (RFA), which yields a necrosis rate of
90–100 % for tumors < 2 cm in diameter and 50 % for
those with a diameter > 3 cm [4, 5]. However, the prox-
imity of the tumor to major vessels, gall bladder, dia-
phragm, and liver surface, as well as the presence of
non-echogenic lesions on ultrasound, present major
restrictions regarding the use of RFA. Consequently,
overall, only 30–40 % of patients may benefit from the
various curative treatments, due to various clinical con-
ditions [6]. Therefore, an alternative local therapeutic
modality, namely stereotactic radiotherapy, is urgently
needed in these clinical settings.
With the development of 3-dimensional conformal
radiotherapy, image-guided treatment, and the resulting
accumulation of knowledge on partial-volume liver tol-
erance, high-dose radiation can now be delivered to focal
liver volumes [7]. Hence, the use of radiotherapy for
small intrahepatic tumors has become feasible as well as
tolerable for patients. Several studies, including pro-
spective and retrospective ones, have demonstrated that
stereotactic body radiotherapy (SBRT) can achieve high
local control and competent OS rates of 65–100 % and
48–82 %, respectively, at 1 year [8–12].
The tumor marker, alpha-fetoprotein (AFP), is de-
tected in approximately 39–65 % of HCC patients, and
has been used as a diagnostic tool [13]. Measurement of
AFP is useful for detecting recurrence and for predicting
survival after locoregional or systemic treatment, based
on the hypothesis of the correlation between AFP level
and tumor activity or tumor burden [14–17]. Although
some recent studies have reported the association be-
tween AFP level and local tumor control or tumor re-
sponse after SBRT [18, 19], the significance of AFP
normalization has yet not been studied in HCC patients
after SBRT, which is an alternative ablative treatment
used worldwide for small HCC. Accordingly, this study
undertook to assess the significance of AFP normalization




Patients who underwent SBRT for primary or recurrent
HCC were prospectively registered at our institution,
and the database of their records between March 2007
and December 2011 was retrospectively reviewed. The
detailed eligibility criteria for SBRT were described in
our previous report [12]. Among 165 total registered pa-
tients, 77 were selected, as they met the following cri-
teria: (1) their AFP levels were > 20 ng/mL before SBRT,
and (2) their AFP levels were checked within three
months after SBRT. This study was approved by the
Institutional Review Board of the Asan Medical Center,
and written informed consent was waived because of the
retrospective nature of the study.
SBRT procedure
The SBRT procedure at our institution was described in
our previous study [12]. At least one week before com-
puted tomography (CT) simulation, three fiducial
markers (Standard Gold Soft Tissue Markers, CIVCO
Medical Solutions, Kalona, IA) were inserted into the
liver parenchyma around the tumors of all patients ex-
cept for those who had surgical clips or compact iodized
oil from previous treatments. Pillows and vacuum molds
were used for patient immobilization: 4-dimensional CT
simulation was carried out (GE LightSpeed RT 16; GE
Healthcare, Waukesha, WI, USA) with free breathing.
The CT series were sorted according to respiratory
phase using 4D imaging software (Advantage 4D version
4.2; GE Healthcare). Gross tumor volume (GTV) was
delineated based on visible gross tumor seen on CT im-
ages at the end-expiratory phase; extension based on
movement within the gating phase (30–70 %) from the
GTV was set as the internal target volume (ITV). Plan-
ning target volume margin was 5 mm from the ITV.
SBRT was planned using multiple coplanar and non-
coplanar beams with energies of 6 or 15 MV. A dose of
10–20 Gy (median, 15 Gy) per fraction was given
over 3–4 consecutive days to a total dose of 30–
60 Gy (median, 45 Gy). Contouring and treatment
planning were done using a 3D-radiotherapy planning
system (Eclipse version 8.0; Varian Medical Systems,
Inc., Palo Alto, CA, USA).
Image guidance, including cone-beam CT and gated
fluoroscopy, was performed before each treatment session
using the On-Board Imager (Varian Medical Systems).
AFP evaluation and assessment of treatment response
Serum AFP levels were measured by chemiluminescent
microparticle immunoassay (ARCHITECT i2000SR;
Abbott, Chicago, IL, USA). AFP normalization was de-
fined as the reduction of AFP to our institutional normal
level (≤ 20 ng/mL) within three months after completion
of SBRT. After treatment, patients were followed up every
1–3 months. Follow-up consisted of physical examina-
tions, complete blood counts, biochemical profiles, AFP,
and dynamic CT or magnetic resonance image studies.
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Statistical analysis
Local failure was defined as recurrence of the treated le-
sion, intrahepatic recurrence was defined as recurrence
within the liver outside of the treated lesion, and extra-
hepatic metastasis was defined as recurrent disease at
any site outside of the liver. Overall and progression-free
survivals were estimated from the date of the start of
SBRT to the date of a patient’s death, the last follow-up
examination, or to the date of tumor recurrence.
Categorical variables for the normalized and non-
normalized groups were compared using the χ2-test,
whereas continuous variables were compared using
Student's t-test. The probability of cumulative survival
was calculated using the Kaplan-Meier method and was
compared using the log-rank test. Univariate and multi-
variate analysis was performed via the Cox proportional
hazards model. A p-value < 0.05 was considered statisti-
cally significant. To reduce potential confounding effects
in this retrospective study, propensity score based
matching analysis was performed. All the possible clin-
ical variables (age, gender, Eastern Cooperative Oncology
Group performance status, Child-Pugh classification,
viral etiology, tumor size, initial AFP, alanine amino-
transferase, albumin, bilirubin, international normalized
ratio, and radiation dose) were included in the propen-
sity score matching. We performed caliper matching on
the PS (nearest available matching). Pairs (normalized and
non-normalized groups) on the PS logit were matched to
within a range of 0.2 multiplied by the standard deviation
[20]. The balance of covariates was measured by their
standardized differences. A difference > 20 % of the abso-
lute value was considered significantly imbalanced. All
statistical analyses were performed using the SPSS statis-
tical package (version 18.0; SPSS Inc., Chicago, IL, USA)
and R software version 2.13 (R Foundation for Statistical
Computing, Vienna, Austria; www.r-project.org). The R
package of MatchIt was used for the propensity score
analysis [21].
Results
Patient characteristics and AFP response
The characteristics of the 77 patients in our study are
summarized in Table 1 according to normalization of
AFP level. The median age was 60 years (range, 39–78
years) and 75.3 % were males. Most patients had an
Eastern Cooperative Oncology Group performance sta-
tus of 0 (54.5 %) or 1 (40.3 %) and were chronic carriers
of the hepatitis B virus (74.0 %). Thirty-seven (48.1 %) of
the 77 patients showed AFP normalization (normalized
group). In the other 40 patients (51.9 %), AFP levels did
not decrease below 20 ng/mL (non-normalized group).
Median follow-up time was 22.2 months (range, 1.8–
68.6 months). Among 77 patients, 73 underwent a
variety of previous treatment. The types of treatments
were as follows: 33 transarterial chemoembolization
(TACE) only; 27 TACE and RFA; 2 TACE and percutan-
eous ethanol injection (PEI); 1 TACE, RFA, and PEI; 7
Resection and TACE; 2 Resection, TACE, and RFA; and
1 RFA only. The median number of previous treatment
sessions was 4 (0–17) and the median period from the
initial diagnosis of HCC to the start of RT was
14.9 months (0.2–176.3 months).
Although baseline characteristics did not differ signifi-
cantly between the two groups, propensity score match-
ing was also performed. After this analysis, 25 matched
pairs of the AFP normalized group vs. the non-
normalized group were created. In this matched cohort,
the baseline characteristics were distributed evenly
between the two groups (Table 1).
AFP response correlated to survival
The median OS and PFS time for all patients were
38.9 months and 10.7 months, respectively. OS at 3-year
was superior in the normalized group to that in the
non-normalized group (62.0 % vs. 44.0 %, p = 0.023).
PFS at 3-year was also superior in the normalized
group to that in the non-normalized group (27.9 % vs.
12.0 %, p = 0.019) (Fig. 1). Intrahepatic recurrence-free
survival and distant metastasis-free survival were signifi-
cantly longer in the normalized group than in the non-
normalized group (p = 0.033 and 0.044, respectively).
However, local control rates did not differ significantly
between these two groups (97.2 % in the normalized
group and 94.7 % in the non-normalized group at 3-year,
p = 0.579) (Fig. 2).
After propensity score matching, OS and PFS were
still significantly longer in the normalized group than
in the non-normalized group (p = 0.017 and 0.049,
respectively) (Fig. 3). Intrahepatic recurrence-free survival
and distant metastasis-free survival showed trends of
longer survival in the normalized group (p = 0.114 and
0.068). The local control rate was 100 % in 50 of the
matched cohort patients.
Independent prognostic significance of AFP normalization
The univariate and multivariate analyses are summarized
in Table 2. On univariate analysis, age, Child-Pugh clas-
sification, tumor size, albumin, bilirubin, radiation dose,
and AFP normalization were identified as significant
parameters of OS. Multivariate analyses revealed that
the following factors had significant effects on OS:
AFP normalization (hazard ratio [HR] = 0.31; 95 % CI,
0.14–0.70; p < 0.005); age (HR = 1.08; 95 % CI, 1.03–
1.14; p < 0.004); and tumor size (HR = 1.66; 95 % CI,
1.14–2.40; p < 0.008).
AFP normalization also had a significant prognostic
value regarding OS and PFS after propensity score
matching (Table 3).
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Discussion
AFP has been reported to be a useful tumor marker for
the detection of recurrence, and a predictive factor for
patient survival after locoregional or systemic treatment
in HCC [14–17]. Shirabe et al. demonstrated that a de-
cline in AFP levels after surgery is a good predictive
Table 1 Patient characteristics
Variables All patients (n = 77) Propensity score matched patients (50 pairs)
Normalized group Non-normalized group P Normalized group Non-normalized group p
(n = 37) (n = 40) (n = 25) (n = 25)
No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%)
Age (years) 0.279 0.929
Median 62 59 58 60
Range 47–78 39–78 50–69 39–78
Gender 0.550 0.747
Male 29 (78.4) 29 (72.5) 19 (76.0) 18 (72.0)
Female 8 (21.6) 11 (27.5) 6 (24.0) 7 (28.0)
ECOG PS 0.197 0.156
0 23 (62.2) 19 (47.5) 16 (64.0) 11 (44.0)
1–2 14 (37.8) 21 (52.5) 9 (36.0) 14 (56.0)
Child-Pugh classification 0.945 0.480
A 28 (75.7) 30 (75.0) 19 (76.0) 21 (84.0)
B 9 (24.3) 10 (25.0) 6 (24.0) 4 (16.0)
Viral etiology 0.402 1.000
HBs-Ag (+) 29 (78.4) 28 (70.0) 20 (80.0) 20 (80.0)
HBs-Ag (−) 8 (21.6) 12 (30.0) 5 (20.0) 5 (20.0)
Tumor size (cm) 0.488 0.344
Median 2.0 1.7 2.1 1.6
Range 0.8–4.5 1.0–4.4 1.0–4.5 1.2–3.6
Initial AFP (ng/mL) 0.187 0.655
Median 48.6 128.0 50.2 113.0
Range 20.8–1870.0 20.3–3250.0 21.2–1870.0 20.3–2490.0
ALT 0.093 0.981
Median 25 28.5 27 25
Range 9–55 11–185 9–55 14–116
Albumin 0.383 0.395
Median 3.6 3.4 3.4 3.6
Range 2.4–4.5 2.4–4.7 2.4–4.5 2.9–4.7
Bilirubin 0.841 0.804
Median 1.1 1.1 1.0 1.0
Range 0.5–3.5 0.6–6.2 0.5–2.9 0.6–6.2
INR 0.550 0.514
Median 1.1 1.1 1.2 1.1
Range 0.9–1.5 0.9–1.7 0.9–1.5 0.9–1.7
Radiation dose 0.909 0.743
Median 45 45 45 45
Range 36–60 36–60 36–60 36–60
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, HBs-Ag hepatitis B surface-antigen, AFP alpha-fetoprotein, ALT alanine
aminotransferase, INR international normalized ratio
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factor for the detection of early recurrence in patients
with HCC [14]. One study showed a favorable decrease
of AFP level after RFA as a prognostic surrogate for pre-
dicting the disease-free survival in HCC [17]. The prog-
nostic value of AFP was also reported in studies on
systemic therapy as well as in those on local therapy. In
the study of Chan et al., the achievement of AFP re-
sponse was an independent prognostic factor for patient
survival, and serial AFP measurements were useful in
monitoring treatment response in patients with unre-
sectable HCC undergoing systemic chemotherapy [15].
Yau et al. also showed that a drop in serum AFP >20 %
during the first six weeks is an exploratory early surro-
gate for both clinical benefit (i.e., complete response,
partial response, or stable disease according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria) and PFS in advanced HCC patients receiving
sorafenib [22].
The significance of the AFP response after external
beam radiotherapy for HCC patients has not been fully
evaluated. Kim et al. evaluated early AFP response as a
predictor of clinical outcome after localized concurrent
chemoradiotherapy (CCRT) for 149 advanced HCC pa-
tients [23]. This study demonstrated that OS and PFS
were longer in AFP responders after CCRT. Lee et al. re-
ported that AFP responders (which were defined as
those with a reduction of > 20 % from the baseline level)
showed significantly better OS after hepatic artery infu-
sion chemotherapy or CCRT than did non-responders
[24]. Other authors also reported association between
Fig. 1 Overall survival (a) and progression-free survival rates (b) of all patients according to alpha-fetoprotein normalization
Fig. 2 Intrahepatic recurrence-free survival (a), distant metastasis-free survival (b), and local control rates (c) of all patients according to
alpha-fetoprotein normalization
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AFP level and local tumor control or tumor response
after SBRT for HCC [18, 19]. However, there has
been no study to evaluate the significance of AFP
normalization in patients with small HCC after abla-
tive radiotherapy, especially SBRT.
In the present study, AFP normalization in patients
with HCC after SBRT was a good prognostic surrogate
for OS and PFS. Our data suggest that patients who
achieve AFP normalization after SBRT have longer
OS and PFS than do non-normalized patients. The
difference in PFS between these two groups was
mainly due to differences in incidence and the pro-
portion of intrahepatic recurrence, and next by the
difference in distant metastasis, while the local con-
trol rate was not significantly different between the
normalized and the non-normalized group. OS and
PFS were still longer in the AFP normalized group
than in the non-normalized group after propensity
score matching. We can assume that the difference in
PFS affected OS, and that non-normalized AFP levels
Fig. 3 Overall survival (a) and progression-free survival rates (b) according to alpha-fetoprotein normalization in the propensity score
matched cohorts
Table 2 Univariate and multivariate analyses of prognostic parameters for overall survival
Variables Univariate Analyses Mutivariate Analyses
P (Cox regression) HR 95 % CI P (Cox regression) HR 95 % CI
Age 0.035 1.05 1.01-1.09 0.004 1.08 1.03-1.14
Gender 0.654 1.19 0.56-2.55 - - -
ECOG PS (0 vs. 1–2) 0.129 1.72 0.85-3.46 - - -
Child-Pugh (A vs. B) 0.011 2.52 1.24-5.13 0.142 2.72 0.72-10.31
Tumor size (cm) 0.016 1.52 1.08-2.15 0.008 1.66 1.14-2.40
preAFP (ng/mL) 0.436 1.00 1.00-1.00 - - -
ALT 0.898 1.01 0.99-1.01 - - -
Albumin 0.050 0.53 0.28-1.00 0.379 1.62 0.55-4.72
Bilirubin 0.027 1.58 1.05-2.36 0.258 1.43 0.77-2.70
INR 0.065 7.99 0.88-72.87 0.400 4.48 0.14-146.79
Radiation dose 0.018 0.94 0.89-0.99 0.079 0.95 0.90-1.01
AFP normalization (yes vs. no) 0.028 0.45 0.22-0.92 0.005 0.31 0.14-0.70
Abbreviations: HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group performance status, HBs-Ag hepatitis B surface-antigen,
preAFP pre-treatment alpha-fetoprotein, ALT alanine aminotransferase, INR international normalized ratio
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reflect the subclinical intrahepatic or extrahepatic
tumor burden, which may be responsible for early re-
currence after treatment. Lee et al. proposed a similar
hypothesis, namely that increased AFP values may be
related to the presence of tumor invasiveness indices,
such as vascular invasion, tumor differentiation, and
intrahepatic metastases, and that differences in tumor
invasiveness may have occurred according to AFP re-
sponse. If so, this could result in a difference in OS
between AFP responders and non-responders [24].
AFP normalization is a simple, rapid, reproducible,
and operator-independent measurement [16] and has
been shown to be a prognostic surrogate. However, stud-
ies on the prognostic value of AFP normalization after
SBRT are difficult due to several factors. First, there is as
of yet no consensus regarding the optimal decrement of
the AFP level. Furthermore, the cut-off level of pre-
treatment AFP that would be adequate in order to apply
AFP normalization as a surrogate is indistinct. Neverthe-
less, in our study we adopted a pre-treatment AFP
level > 20 ng/mL as an inclusion criterion. Almost all of
the patients who were analyzed in this study had an ALT
level within the normal range, and most patients were
chronic carriers of hepatitis B virus, i.e., they had no rep-
licate activity. As patients with a high viral load were
treated with an antiviral agent, they were in a stable state
under viral suppression. Therefore, we could avoid
disturbances caused by chronic hepatitis. However,
when clinicians apply AFP normalization as a prog-
nosticator, they should be cautious regarding the liver
condition of their patients. Second, interpretation of
AFP normalization could be ambiguous because of
variable patient and tumor characteristics. In our
study, all patients were treated with SBRT for small
viable HCC as the salvage treatment intent after
undergoing several previous severe treatments, namely
transarterial chemoembolization, hepatectomy, and/or
RFA. These states may be related to more frequent
progression or intrahepatic or extrahepatic recurrence
than is seen in treatment-naïve patients who were en-
rolled in previous studies and who demonstrated sig-
nificant post-treatment AFP after surgery or RFA.
Third, the value of AFP normalization in our study
can only be applied in patients who have elevated
AFP levels before treatment. Future studies regarding
serum protein induced by vitamin K absence or
antagonist-II (PIVKA-II) could reveal the usefulness
of this tumor marker for HCC patients with a normal
AFP level [24]. Finally, although this study was per-
formed using 20 ng/mL as the cut-off level for ele-
vated AFP, among 165 patients who underwent SBRT,
only 77 patients were included in our study. Further-
more, the sample size was further decreased after
propensity score matching analysis. Therefore, further
studies with a greater number of patients could provide a
more relevant answer regarding AFP normalization.
Despite these limitations, ours is the first study show-
ing the value of AFP normalization as a prognostic sur-
rogate in OS and PFS in two cohorts that were evenly
distributed through propensity score matching analysis.
AFP normalization seems to be a useful tool for predict-
ing clinical outcomes in small HCC after local ablative
therapy.
Conclusions
AFP normalization in patients with small HCC within
three months after SBRT is a prognostic surrogate for
OS and PFS. Patients who achieve AFP normalization
after SBRT have longer OS and PFS than do those in a
non-normalized group. AFP monitoring should be con-
sidered a useful tool in HCC patients with an elevated
AFP level before SBRT.
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